LUNG ALERT
Using molecular markers as a means of predicting prognosis and outcomes in the treatment of lung cancer
Senior House Officer, Mater Infirmorum Hospital, Belfast; jenny.c@doctors.org.uk
| The first 150 words of the full text of this article appear below. |
Zheng Z, Chen T, Li X. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. NEJM 2007;356:80008.
This study evaluated the potential association between the expression of two specific proteins and treatment outcomes of patients with early non-small-cell lung cancer.
Increased expression of the gene RRM1 (regulatory subunit of ribonucleotide reductase) has been shown to reduce metastases, inhibit development of lung tumours and prolong survival. Similar data have been shown for ERCC1 (excision repair cross-complementation group 1).
The study group consisted of 187 patients who had undergone thoracotomy for resection of stage 1 non-small-cell lung cancer and had had no other treatment.
The expression of RRM1, ERCC1 and PTEN (phosphatase and tensin homologue) were measured with a new fully automated and quantitative system, and the genetic results compared with clinical outcomes. RRM1 expression correlated with the expression of ERCC1 but not with PTEN.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
